A recent ruling from the District Court for the District of Columbia has denied Corewell Health William Beaumont University Hospital's request for a preliminary injunction. The hospital sought to regain access to discounted drug pricing for Orphan Drugs under the Section 340B program after losing its Disproportionate Share Hospital (DSH) status. This decision affects the hospital's financial operations and its ability to provide affordable medications to patients.

The case, Corewell Health William Beaumont University Hospital v. Kennedy, Civil Action No. 2026-3111, centers on the hospital's participation in the Section 340B program, which allows certain healthcare providers to purchase drugs at reduced prices. The ruling is significant as it highlights the complexities of healthcare regulations and the implications for hospitals reliant on such programs.

Background

Corewell Health William Beaumont University Hospital, located in suburban Detroit, has participated in the Section 340B program since 2019. This program enables hospitals to purchase outpatient drugs at significantly reduced prices, benefiting low-income patients by increasing access to necessary medications. Beaumont qualified as a DSH from 2024 to early 2026, allowing it to purchase Orphan Drugs at discounted prices.

In January 2026, Beaumont expressed concern that it might not meet the criteria to maintain its DSH status due to a projected decline in its disproportionate share adjustment percentage. To avoid losing access to discounted drug pricing, the hospital voluntarily changed its designation to a Rural Referral Center (RRC). However, after realizing its projections were incorrect, Beaumont attempted to re-register as a DSH. Unfortunately, the Health Resources and Services Administration (HRSA) informed the hospital that its application was incomplete, resulting in a loss of access to discounted Orphan Drugs for several months.

The Ruling

The court, presided over by Judge Carl J. Nichols, ruled against Beaumont's motion for a preliminary injunction. The court found that while Beaumont had standing to bring the case, it failed to demonstrate that it faced irreparable harm without the requested relief. The ruling stated, "Although Beaumont does have standing, it has failed to show that it faces irreparable harm absent relief and the other factors do not weigh strongly in favor of an injunction."

The court emphasized that Beaumont's financial loss did not meet the threshold for irreparable harm, as economic harm alone does not typically qualify unless it threatens the very existence of the business. Judge Nichols noted that Beaumont's claimed losses, while significant, did not demonstrate an imminent threat to the hospital's operations.

Impact

This ruling has important implications for Corewell Health Beaumont University Hospital and similar healthcare providers. By denying the preliminary injunction, the court has upheld HRSA's registration process, which requires hospitals to navigate a complex system to maintain their eligibility for discounted drug pricing. This decision may deter other hospitals from pursuing similar claims, as it reinforces the idea that economic losses, even substantial ones, may not suffice to warrant immediate judicial intervention.

The ruling also raises questions about the administrative processes governing the Section 340B program. It highlights the need for healthcare providers to be vigilant in maintaining their eligibility and understanding the implications of their designations. The court's decision may prompt hospitals to seek clearer guidelines from HRSA regarding the registration process and its impact on drug pricing.

What's Next

Corewell Health Beaumont University Hospital has the option to appeal the court's decision. The outcome of this case could influence future litigation involving the Section 340B program and the administrative requirements imposed by HRSA. As hospitals continue to navigate the complexities of healthcare regulations, this ruling serves as a reminder of the challenges they face in securing affordable medications for their patients.